Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Heilongjiang ZBD Pharmaceutical Secures Approval for Chemical Raw Material Drug Listing

MT NewswiresDec 17, 2024 03:44 ET

ZBD Pharma Gets China Approval for Antibacterial Injection

MT NewswiresDec 3, 2024 02:59 ET

Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Stock Price Dropped 3.8% Last Week; Private Equity Firms Would Not Be Happy

Simply Wall StNov 18, 2024 22:22 ET

Report for the third quarter of 2024 of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

SZSIOct 29, 2024 12:00 ET · Announcements

While Shareholders of Heilongjiang ZBD Pharmaceutical (SHSE:603567) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown

Simply Wall StOct 25, 2024 00:39 ET

We Think Heilongjiang ZBD Pharmaceutical (SHSE:603567) Can Stay On Top Of Its Debt

Simply Wall StOct 3, 2024 23:52 ET

China Rejects ZBD Pharmaceutical's Application For Skin Infection Drug

MT NewswiresAug 27, 2024 01:56 ET

Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2024 Semi-Annual Report

SZSIAug 26, 2024 12:00 ET · Announcements

Summary of the 2024 semi-annual report of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.

SZSIAug 26, 2024 12:00 ET · Announcements

Improved Earnings Required Before Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Shares Find Their Feet

Simply Wall StAug 20, 2024 23:34 ET

Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Annual Report 2023 - Revised Edition Summary.

SZSIAug 7, 2024 12:00 ET · Announcements

Heilongjiang ZBD Pharmaceutical Co., Ltd. 2023 Semi-Annual Report - Revised Edition Summary.

SZSIAug 7, 2024 12:00 ET · Announcements

Heilongjiang ZBD Pharmaceutical Co., Ltd. Q1/2024 Revised Report

SZSIAug 7, 2024 12:00 ET · Announcements

Heilongjiang ZBD Pharmaceutical Co., Ltd. Annual Report 2023 - Revised Edition.

SZSIAug 7, 2024 12:00 ET · Announcements

Heilongjiang ZBD Pharmaceutical Co., Ltd. 2023 Interim Report - Revised Version.

SZSIAug 7, 2024 12:00 ET · Announcements

Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Q3 2023 Revised Report

SZSIAug 7, 2024 12:00 ET · Announcements

Heilongjiang ZBD Pharmaceutical Co., Ltd. Q1 2023 Revised Report

SZSIAug 7, 2024 12:00 ET · Announcements

Private Equity Firms Are Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Biggest Owners and Were Hit After Market Cap Dropped CN¥517m

Simply Wall StJul 29, 2024 18:18 ET

ZBD Pharmaceutical Gets Nod to Market Bromhexine Hydrochloride Injection

MT NewswiresJul 19, 2024 02:19 ET